Contineum Therapeutics Files 2025 Proxy Statement

Ticker: CTNM · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1855175

Contineum Therapeutics, Inc. DEF 14A Filing Summary
FieldDetail
CompanyContineum Therapeutics, Inc. (CTNM)
Form TypeDEF 14A
Filed DateApr 29, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, executive-compensation

TL;DR

Contineum Proxy filed: vote on exec pay & board for 2024 fiscal year.

AI Summary

Contineum Therapeutics, Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting on June 26, 2025. The company, formerly known as Pipeline Therapeutics, Inc. until April 5, 2021, is based in San Diego, CA. The filing details executive compensation and other corporate governance matters for the fiscal year ending December 31, 2024.

Why It Matters

This filing provides shareholders with crucial information regarding executive compensation, board nominations, and other voting matters, enabling informed participation in the company's governance.

Risk Assessment

Risk Level: low — This is a routine annual filing (DEF 14A) providing information to shareholders, not announcing new material events.

Key Numbers

  • 001-42001 — SEC File Number (Identifies the company's filings with the SEC.)
  • 25887238 — Film Number (Internal SEC processing number for the filing.)

Key Players & Entities

  • Contineum Therapeutics, Inc. (company) — Registrant
  • Pipeline Therapeutics, Inc. (company) — Former company name
  • San Diego, CA (location) — Company headquarters
  • April 29, 2025 (date) — Filing date
  • June 26, 2025 (date) — Annual meeting date
  • December 31, 2024 (date) — Fiscal year end

FAQ

What is the primary purpose of this DEF 14A filing?

The primary purpose is to provide shareholders with information regarding the annual meeting of stockholders, including details on director nominations, executive compensation, and other matters to be voted upon.

When is the Contineum Therapeutics, Inc. annual meeting scheduled?

The annual meeting is scheduled for June 26, 2025.

What was Contineum Therapeutics, Inc. formerly known as?

Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc.

What is the company's principal executive office location?

The company's principal executive office is located at 3565 General Atomics Court, Suite 200, San Diego, CA 92121.

For which fiscal year does this proxy statement provide information?

This proxy statement provides information for the fiscal year ending December 31, 2024.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Contineum Therapeutics, Inc. (CTNM).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.